The breast cancer screening test market size has grown strongly in recent years. It will grow from $2.49 billion in 2025 to $2.69 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing breast cancer incidence awareness, widespread deployment of mammography screening programs, expansion of diagnostic laboratory infrastructure, availability of standardized screening guidelines, growing public health screening initiatives.
The breast cancer screening test market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising adoption of personalized cancer screening protocols, increasing use of ai-powered diagnostic tools, expansion of genetic testing adoption, growing focus on early-stage cancer detection, increasing investments in preventive oncology services. Major trends in the forecast period include increasing adoption of advanced imaging-based screening tests, rising use of genetic and molecular diagnostics, growing integration of ai in image interpretation, expansion of multi-modal screening approaches, enhanced focus on early and preventive diagnostics.
The increasing incidence of breast cancer is anticipated to drive the growth of the breast cancer screening test market. Breast cancer involves the abnormal and uncontrolled growth of cells in breast tissue, which can develop into a tumor and potentially spread to other body parts. The rise in breast cancer cases is attributed to the aging global population, as older age significantly raises the risk of developing the disease, and longer life expectancies mean a greater number of individuals are at risk. Screening tests for breast cancer are essential for identifying the disease in its early stages, thereby improving treatment outcomes and lowering mortality rates. For example, in March 2025, Breastcancer.org, a nonprofit organization based in the US, projected that approximately 316,950 women would be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS). Additionally, in December 2024, the Public Health Agency of Canada reported that an estimated 28,600 women in Canada were expected to be diagnosed with breast cancer in 2022, with 5,500 fatalities anticipated. As a result, the rising prevalence of breast cancer is contributing to the expansion of the breast cancer screening test market.
Leading companies in the breast cancer screening test sector are prioritizing the development of cutting-edge solutions such as mobile screening units to improve accessibility, increase early detection, and extend services to underserved or remote regions. These mobile units are transportable facilities equipped with diagnostic imaging technologies like mammography, designed to deliver on-site breast cancer screening in areas lacking adequate healthcare access. For instance, in September 2024, Granules India Ltd., a pharmaceutical company based in India, introduced the Breast Health Express to promote breast cancer screening in disadvantaged communities. Outfitted with advanced mammography and ultrasound systems, the unit facilitates quality screenings while on the move. This initiative aims to bring early detection services to rural and underserved areas, helping to ensure access to critical healthcare for women in these regions.
In August 2024, Hitachi High-Tech Corporation, a Japan-based producer of electronic and electrical equipment, entered into a strategic alliance with Gencurix Inc. for an undisclosed amount. Through this collaboration, Hitachi seeks to utilize its knowledge in in vitro diagnostics and digital technologies to create accurate and efficient molecular diagnostics for cancer. Gencurix Inc., headquartered in South Korea, specializes in breast cancer testing solutions.
Major companies operating in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., BD (Becton Dickinson and Company), Agilent Technologies Inc.
North America was the largest region in the breast cancer screening test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer screening test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast cancer screening test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the breast cancer screening test market by increasing costs of imported imaging equipment, diagnostic reagents, genetic testing kits, and advanced laboratory instruments. Diagnostic centers and hospitals in North America and Europe are most affected due to dependence on imported imaging systems and consumables, while Asia-Pacific faces higher costs for test kit manufacturing and exports. These tariffs are increasing screening service costs and slowing equipment upgrades. However, they are also supporting local manufacturing of diagnostic kits, regional laboratory expansion, and domestic development of screening technologies.
The breast cancer screening test market research report is one of a series of new reports that provides breast cancer screening test market statistics, including breast cancer screening test industry global market size, regional shares, competitors with a breast cancer screening test market share, detailed breast cancer screening test market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer screening test industry. This breast cancer screening test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A breast cancer screening test is a medical procedure or diagnostic method designed to detect breast cancer at an early stage, often before any symptoms develop. The main objective of screening is to discover cancer when it is most treatable, thereby potentially lowering mortality rates and enhancing patient outcomes. Early diagnosis through breast cancer screening enables timely treatment and leads to a more favorable prognosis.
The primary types of diagnostic tests used in breast cancer screening include blood marker tests, imaging tests, genetic tests, and immunohistochemistry tests. Blood marker tests identify and quantify specific substances in the blood to support disease detection, monitoring, or risk evaluation. Different levels of risk - high-risk, moderate-risk, and average-risk populations - are considered, and the tests are utilized by various end users, including hospitals, diagnostic centers, cancer institutes, and research laboratories.
The breast cancer screening test market consists of revenues earned by entities by providing services such as early detection, risk assessment, and tumor detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer screening test market also consists of sales of products including ultrasound equipment, screening software, and breast self-examination kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The breast cancer screening test market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising adoption of personalized cancer screening protocols, increasing use of ai-powered diagnostic tools, expansion of genetic testing adoption, growing focus on early-stage cancer detection, increasing investments in preventive oncology services. Major trends in the forecast period include increasing adoption of advanced imaging-based screening tests, rising use of genetic and molecular diagnostics, growing integration of ai in image interpretation, expansion of multi-modal screening approaches, enhanced focus on early and preventive diagnostics.
The increasing incidence of breast cancer is anticipated to drive the growth of the breast cancer screening test market. Breast cancer involves the abnormal and uncontrolled growth of cells in breast tissue, which can develop into a tumor and potentially spread to other body parts. The rise in breast cancer cases is attributed to the aging global population, as older age significantly raises the risk of developing the disease, and longer life expectancies mean a greater number of individuals are at risk. Screening tests for breast cancer are essential for identifying the disease in its early stages, thereby improving treatment outcomes and lowering mortality rates. For example, in March 2025, Breastcancer.org, a nonprofit organization based in the US, projected that approximately 316,950 women would be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS). Additionally, in December 2024, the Public Health Agency of Canada reported that an estimated 28,600 women in Canada were expected to be diagnosed with breast cancer in 2022, with 5,500 fatalities anticipated. As a result, the rising prevalence of breast cancer is contributing to the expansion of the breast cancer screening test market.
Leading companies in the breast cancer screening test sector are prioritizing the development of cutting-edge solutions such as mobile screening units to improve accessibility, increase early detection, and extend services to underserved or remote regions. These mobile units are transportable facilities equipped with diagnostic imaging technologies like mammography, designed to deliver on-site breast cancer screening in areas lacking adequate healthcare access. For instance, in September 2024, Granules India Ltd., a pharmaceutical company based in India, introduced the Breast Health Express to promote breast cancer screening in disadvantaged communities. Outfitted with advanced mammography and ultrasound systems, the unit facilitates quality screenings while on the move. This initiative aims to bring early detection services to rural and underserved areas, helping to ensure access to critical healthcare for women in these regions.
In August 2024, Hitachi High-Tech Corporation, a Japan-based producer of electronic and electrical equipment, entered into a strategic alliance with Gencurix Inc. for an undisclosed amount. Through this collaboration, Hitachi seeks to utilize its knowledge in in vitro diagnostics and digital technologies to create accurate and efficient molecular diagnostics for cancer. Gencurix Inc., headquartered in South Korea, specializes in breast cancer testing solutions.
Major companies operating in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., BD (Becton Dickinson and Company), Agilent Technologies Inc.
North America was the largest region in the breast cancer screening test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer screening test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breast cancer screening test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the breast cancer screening test market by increasing costs of imported imaging equipment, diagnostic reagents, genetic testing kits, and advanced laboratory instruments. Diagnostic centers and hospitals in North America and Europe are most affected due to dependence on imported imaging systems and consumables, while Asia-Pacific faces higher costs for test kit manufacturing and exports. These tariffs are increasing screening service costs and slowing equipment upgrades. However, they are also supporting local manufacturing of diagnostic kits, regional laboratory expansion, and domestic development of screening technologies.
The breast cancer screening test market research report is one of a series of new reports that provides breast cancer screening test market statistics, including breast cancer screening test industry global market size, regional shares, competitors with a breast cancer screening test market share, detailed breast cancer screening test market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer screening test industry. This breast cancer screening test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A breast cancer screening test is a medical procedure or diagnostic method designed to detect breast cancer at an early stage, often before any symptoms develop. The main objective of screening is to discover cancer when it is most treatable, thereby potentially lowering mortality rates and enhancing patient outcomes. Early diagnosis through breast cancer screening enables timely treatment and leads to a more favorable prognosis.
The primary types of diagnostic tests used in breast cancer screening include blood marker tests, imaging tests, genetic tests, and immunohistochemistry tests. Blood marker tests identify and quantify specific substances in the blood to support disease detection, monitoring, or risk evaluation. Different levels of risk - high-risk, moderate-risk, and average-risk populations - are considered, and the tests are utilized by various end users, including hospitals, diagnostic centers, cancer institutes, and research laboratories.
The breast cancer screening test market consists of revenues earned by entities by providing services such as early detection, risk assessment, and tumor detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer screening test market also consists of sales of products including ultrasound equipment, screening software, and breast self-examination kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Breast Cancer Screening Test Market Characteristics
3. Breast Cancer Screening Test Market Supply Chain Analysis
4. Global Breast Cancer Screening Test Market Trends and Strategies
5. Breast Cancer Screening Test Market Analysis of End Use Industries
7. Global Breast Cancer Screening Test Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Breast Cancer Screening Test Total Addressable Market (TAM) Analysis for the Market
9. Breast Cancer Screening Test Market Segmentation
10. Breast Cancer Screening Test Market Regional and Country Analysis
11. Asia-Pacific Breast Cancer Screening Test Market
12. China Breast Cancer Screening Test Market
13. India Breast Cancer Screening Test Market
14. Japan Breast Cancer Screening Test Market
15. Australia Breast Cancer Screening Test Market
16. Indonesia Breast Cancer Screening Test Market
17. South Korea Breast Cancer Screening Test Market
18. Taiwan Breast Cancer Screening Test Market
19. South East Asia Breast Cancer Screening Test Market
20. Western Europe Breast Cancer Screening Test Market
21. UK Breast Cancer Screening Test Market
22. Germany Breast Cancer Screening Test Market
23. France Breast Cancer Screening Test Market
24. Italy Breast Cancer Screening Test Market
25. Spain Breast Cancer Screening Test Market
26. Eastern Europe Breast Cancer Screening Test Market
27. Russia Breast Cancer Screening Test Market
28. North America Breast Cancer Screening Test Market
29. USA Breast Cancer Screening Test Market
30. Canada Breast Cancer Screening Test Market
31. South America Breast Cancer Screening Test Market
32. Brazil Breast Cancer Screening Test Market
33. Middle East Breast Cancer Screening Test Market
34. Africa Breast Cancer Screening Test Market
36. Breast Cancer Screening Test Market Competitive Landscape and Company Profiles
37. Breast Cancer Screening Test Market Other Major and Innovative Companies
40. Breast Cancer Screening Test Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Breast Cancer Screening Test Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses breast cancer screening test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for breast cancer screening test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer screening test market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Diagnostic Test Type: Blood Marker Test; Imaging Test; Genetic Test; Immunohistochemistry Test2) By Risk Level: High-risk Population; Moderate-risk Population; Average-risk Population
3) By End User: Hospitals; Diagnostic Centres; Cancer Institutes; Research Laboratories
Subsegments:
1) By Blood Marker Test: Circulating Tumor Cells (Ctcs) Test; Gene Expression Profiling Test; Circulating Tumor Dna (Ctdna) Test; Proteomic Biomarker Test2) By Imaging Test: Mammography; Magnetic Resonance Imaging Screening Test; Molecular Breast Imaging Test; Positron Emission Mammography; Ultrasound
3) By Genetic Test: Fluorescence In Situ Hybridization; Her Gene Test
4) By Immunohistochemistry (Ihc) Test: Estrogen Receptor (Er) Test; Ki-67 Proliferation Marker Test; Progesterone Receptor (Pr) Test; Her2 Or Neu Test
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthcare GmbH; Fujifilm Corporation; Koninklijke Philips NV; GE HealthCare Technologies Inc.; Quest Diagnostics Incorporated; Hologic Inc.; Hitachi High-Tech Corporation; Exact Sciences Corporation; Natera Inc.; Myriad Genetics Inc.; Canon Medical Systems Corporation; Provista Diagnostics Inc.; Niramai Health Analytix Pvt. Ltd.; Kheiron Medical Technologies Limited; UE LifeSciences Inc.; BD (Becton Dickinson and Company); Agilent Technologies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Breast Cancer Screening Test market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Siemens Healthcare GmbH
- Fujifilm Corporation
- Koninklijke Philips NV
- GE HealthCare Technologies Inc.
- Quest Diagnostics Incorporated
- Hologic Inc.
- Hitachi High-Tech Corporation
- Exact Sciences Corporation
- Natera Inc.
- Myriad Genetics Inc.
- Canon Medical Systems Corporation
- Provista Diagnostics Inc.
- Niramai Health Analytix Pvt. Ltd.
- Kheiron Medical Technologies Limited
- UE LifeSciences Inc.
- BD (Becton Dickinson and Company)
- Agilent Technologies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.69 Billion |
| Forecasted Market Value ( USD | $ 3.68 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
